Product Description
Mechanisms of Action: DNA Adduct
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Nasal,Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Denmark | European Medicines Agency | Finland | Iceland | Ireland | Lithuania | Pakistan | Peru | Poland | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: Seqirus
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: COVID-19|Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-003953-43 | P3 |
Completed |
Influenza, Human|COVID-19 |
2022-11-15 |
|
| 2016-004753-33 | P3 |
Active, not recruiting |
Influenza, Human |
2021-02-22 |